Kinecteen

Methylphenidate Hydrochloride, the active ingredient in Kinecteen, is a Central nervous system stimulant presented as an oral dosage form for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in appropriate patient populations.

GNH USA supplies Kinecteen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate Hydrochloride is a central nervous system stimulant used in the management of specific neurobehavioral disorders.

- Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity. - Narcolepsy: decreases excessive daytime sleepiness and reduces cataplexy episodes.

Methylphenidate Hydrochloride may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Nausea: feeling of stomach upset.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, tachycardia, or arrhythmia. - Psychotic symptoms: hallucinations or severe agitation. - Severe allergic reaction: rash, swelling, or anaphylaxis.

When prescribing or dispensing Methylphenidate Hydrochloride, several safety considerations should be observed.

- Assess cardiovascular status: obtain baseline blood pressure and heart rate. - Monitor psychiatric symptoms: watch for mood changes, anxiety, or emergence of psychosis. - Avoid use in patients with known hypersensitivity: discontinue if allergic reaction occurs. - Use caution in patients with seizure disorder: evaluate risk versus benefit. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Methylphenidate Hydrochloride can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular side effects. - Antihypertensive agents: may reduce blood pressure‑lowering effect.

Moderate Interactions (Monitor Closely):\n- CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate plasma levels. - Antacids: can alter gastrointestinal absorption. - Alcohol: may exacerbate central nervous system stimulation.